Michael Wang
YOU?
Author Swipe
View article: Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL) Open
Purpose: An unmet treatment need remains for relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), including the follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) subtypes. The PI3K/AKT/mTOR pathway is …
View article: Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma Open
The benefit of rituximab maintenance after first-line (1L) bendamustine and rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective s…
Man Plus Machine: A Randomized Control Trial of Artificial Intelligence Including the Impact of Adjunctive Polyp Detection Techniques Open
Background and Aims Computer‐aided polyp detection tools (CADe) utilizing artificial intelligence (AI) have been shown to demonstrate benefit with improved polyp detection during colonoscopy. Questions remain around the impact of CADe when…
View article: Olfactory biopsy analysis of Alzheimer’s pathobiology across disease stages
Olfactory biopsy analysis of Alzheimer’s pathobiology across disease stages Open
Alzheimer’s Disease (AD) is a neurodegenerative condition affecting millions worldwide. Defining early pathobiological events remains challenging, in part due to inaccessibility of neural tissue. Because olfactory neurons are accessible, a…
View article: Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study Open
Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting …
View article: Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy
Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy Open
Introduction: Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL in the US and after ≥2 prior lines of therapy (LoT) including a BTKi in the EU. In the pivotal ZUMA-2 Cohort 1 study, brexu-cel induced …
View article: Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes
Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes Open
Background Emerging evidence suggests that baseline physical function may predict the toxicity of chimeric antigen receptor (CAR) T-cell therapy; however, there is no consensus on how best to evaluate physical function in this setting. The…
View article: The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells
The switch of TCA cycle mode determines the fate of pirtobrutinib-tolerant persister cells Open
Background Drug-tolerant persister (DTP) cells are increasingly recognized as a key contributor to therapy resistance in cancer patients. In mantle cell lymphoma (MCL), the mechanisms by which DTP cells adapt to treatments and develop resi…
Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial Open
Introduction: Lenalidomide with rituximab (R2) as first line treatment for patients with previously untreated follicular lymphoma (FL) has shown its efficacy in former trials, however, long-term outcomes of this treatment are unknown. Here…
View article: Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study
Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study Open
Introduction: MCL is a rare B-cell non-Hodgkin lymphoma typically treated with first-line (1L) chemoimmunotherapy (CIT). While Bruton tyrosine kinase inhibitors (BTKis) are approved in CIT combinations in TN MCL, novel 1L chemotherapy-free…
View article: Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma
Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma Open
Background CAR-T therapy has demonstrated improved survival in patients with relapsed, refractory large B cell lymphoma (R/R LBCL). While the putative cell of origin (COO) (germinal center B-cell [GCB] vs non-GCB) impacts prognosis and tre…
mRNA Therapeutics in Non-small Cell Lung Cancer (NSCLC) Open
The treatment of non-small cell lung cancer had remained the top cause of death globally, is one important area in oncology where messenger RNA therapy has shown promise. In contrast with traditional treatments, mRNA therapeutics offer qui…
<b>Lipids engage a kidney-brain GDF15 axis</b><b>to suppress food intake</b> Open
Growth differentiation factor 15 (GDF15) is an anorectic and weight-loss inducing hormone that responds to stimuli like endoplasmic reticulum stress, exercise, metformin and more recently dietary lipids. Given its potential as an anti-obes…
View article: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study Open
Relapsed/refractory (R/R) follicular lymphoma (FL) is a chronic disease often requiring multiple lines of therapy. Covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy has resulted in variable response rates, yet patients invariabl…
View article: SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma
SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is an incurable subtype of B-cell non-Hodgkin lymphoma. Despite multiple approved Bruton tyrosine kinase inhibitors (BTKis), resistance to BTKi continues to pose a major clinical challenge. The transcription fact…
View article: Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis Open
Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective…
View article: TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma Open
Bruton tyrosine kinase inhibitors (BTKis) and cell therapy have successfully been used to treat mantle cell lymphoma (MCL). However, therapy resistance inevitably emerges. Cancer cells can progressively develop stable resistance by travers…
<b>Metformin Boosts Intestinal Lipid sensing via GIP to Suppress Feeding</b> Open
An acute rise of lipids in the upper small intestine (USI) of rodents and humans triggers lipid-sensing pathways to lower food intake. However, USI lipid sensing fails to lower feeding in high fat (HF) fed conditions, and the underlying me…
<b>Metformin Boosts Intestinal Lipid sensing via GIP to Suppress Feeding</b> Open
An acute rise of lipids in the upper small intestine (USI) of rodents and humans triggers lipid-sensing pathways to lower food intake. However, USI lipid sensing fails to lower feeding in high fat (HF) fed conditions, and the underlying me…
View article: YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma
YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma Open
Nongenetic transcription evolution has been increasingly explored and recognized to drive tumor cell progression and therapeutic resistance. As the regulation hub of transcription machinery, cyclin-dependent kinase 9 (CDK9) is the gatekeep…
View article: A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma Open
Follicular lymphoma (FL) has a clinical course that is often characterized by high response rates to first-line therapy, followed by multiple relapses over a prolonged natural history. Currently, there are multiple possible approaches to f…
View article: Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma Open
PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall surv…
Strategies to Develop Regenerative Medicine Approaches for Olfactory Disorders Open
Olfactory loss affects more than 12% of the population, with prevalence increasing in aging individuals. Multiple conditions can lead to a loss of smell (hyposmia or anosmia), including post-viral damage from coronavirus disease 2019 (COVI…
View article: Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas Open
Background Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment …
YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma Open
Non-genetic transcription evolution has been increasingly explored and recognized to drive tumor cell progression and therapeutic resistance. As the regulation hub of transcription machinery, cyclin-dependent kinase 9 (CDK9) is the gatekee…